跳转至内容
Merck
CN
  • Truncating NFKB1 variants cause combined NLRP3 inflammasome activation and type I interferon signaling and predispose to necrotizing fasciitis.

Truncating NFKB1 variants cause combined NLRP3 inflammasome activation and type I interferon signaling and predispose to necrotizing fasciitis.

Cell reports. Medicine (2024-04-10)
Katariina Nurmi, Kristiina Silventoinen, Salla Keskitalo, Kristiina Rajamäki, Vesa-Petteri Kouri, Matias Kinnunen, Sami Jalil, Rocio Maldonado, Kirmo Wartiovaara, Elma Inés Nievas, Silvina Paola Denita-Juárez, Christopher J A Duncan, Outi Kuismin, Janna Saarela, Inka Romo, Timi Martelius, Jukka Parantainen, Arzu Beklen, Marcelina Bilicka, Sampsa Matikainen, Dan C Nordström, Meri Kaustio, Ulla Wartiovaara-Kautto, Outi Kilpivaara, Christoph Klein, Fabian Hauck, Tiina Jahkola, Timo Hautala, Markku Varjosalo, Goncalo Barreto, Mikko R J Seppänen, Kari K Eklund
摘要

In monogenic autoinflammatory diseases, mutations in genes regulating innate immune responses often lead to uncontrolled activation of inflammasome pathways or the type I interferon (IFN-I) response. We describe a mechanism of autoinflammation potentially predisposing patients to life-threatening necrotizing soft tissue inflammation. Six unrelated families are identified in which affected members present with necrotizing fasciitis or severe soft tissue inflammations. Exome sequencing reveals truncating monoallelic loss-of-function variants of nuclear factor κ light-chain enhancer of activated B cells (NFKB1) in affected patients. In patients' macrophages and in NFKB1-variant-bearing THP-1 cells, activation increases both interleukin (IL)-1β secretion and IFN-I signaling. Truncation of NF-κB1 impairs autophagy, accompanied by the accumulation of reactive oxygen species and reduced degradation of inflammasome receptor nucleotide-binding oligomerization domain, leucine-rich repeat-containing protein 3 (NLRP3), and Toll/IL-1 receptor domain-containing adaptor protein inducing IFN-β (TRIF), thus leading to combined excessive inflammasome and IFN-I activity. Many of the patients respond to anti-inflammatory treatment, and targeting IL-1β and/or IFN-I signaling could represent a therapeutic approach for these patients.

材料
产品编号
品牌
产品描述

Roche
cOmplete蛋白酶抑制剂Cocktail, Tablets provided in EASYpacks
Sigma-Aldrich
Rapamycin, ≥95% (HPLC), powder
Sigma-Aldrich
自噬抑制剂,3-MA, Autophagy Inhibitor, 3-MA, CAS 5142-23-4, is a cell-permeable autophagic sequestration blocker. Acts as an inhibitor of III PI3-Kinase.
Sigma-Aldrich
抗干扰素-α/β受体链 2 抗体,克隆 MMHAR-2, clone MMHAR-2, Chemicon®, from mouse
Sigma-Aldrich
Octoclothepin 马来酸盐, solid